Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04161248 | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | EARLY_PHASE1 | ACTIVE NOT_RECRUITING | 40 | — | — | Sep 2, 2020 | Dec 31, 2026 | May 12, 2026 | 4 | Canada |
| Arm | Type | Description |
|---|---|---|
| Venetoclax + R-GDP | EXPERIMENTAL | - |
| Glofitamab + R-GDP | EXPERIMENTAL | - |
| Tafasitamab + R-GDP | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Venetoclax | DRUG | Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP |
| Rituximab Injection | DRUG | 375 mg/m2 - Day 1, cycle 1. |
| Rituximab SC | DRUG | 1400 mg fixed dose - Day 1, cycle 2 and 3 |
| Gemcitabine | DRUG | 1000 mg/m2 - Day 1 to day 8 |
| Dexamethasone | DRUG | 40 mg daily - Day 1 to day 4 |
| Cisplatin | DRUG | 75mg/m2 - Day 1 |
| Glofitamab | DRUG | Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP |
| Tafasitamab | DRUG | Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15) |
Inclusion Criteria: * Patients with histologic diagnosis for one of the following histologies according to the World Health Organization: documented at initial diagnosis or at relapse: * Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphom...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Soligenix, Inc. | SNGX | 1 | PHASE3 | Hypericin |
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | — | Undisclosed |